Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03327402 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03327402 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 24 participants.
The verdict
NCT03327402, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465
Interventions
- DRUG SHP465
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-03-13 |
| Est. Completion | 2018-10-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03327402
The ClinicalTrials.gov registry entry for NCT03327402 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SHP465 is the first listed.
NCT03327402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03327402 about?
NCT03327402 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)". The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465
What is the current status of trial NCT03327402?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-03-13. Estimated completion is 2018-10-05.
What interventions are being tested in trial NCT03327402?
The interventions under investigation include: SHP465 (DRUG).
Who is sponsoring clinical trial NCT03327402?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.